tetano
Editor, Senior Moderator
J Med Virol
. 2023 May;95(5):e28774.
doi: 10.1002/jmv.28774. Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
Siew-Wai Fong[SUP] 1 [/SUP], Yun Shan Goh[SUP] 1 [/SUP], Anthony Torres-Ruesta[SUP] 1 [/SUP], Zi Wei Chang[SUP] 1 [/SUP], Yi-Hao Chan[SUP] 1 [/SUP], Vanessa Kexin Neo[SUP] 1 [/SUP], Bernett Lee[SUP] 2 3 [/SUP], Kaibo Duan[SUP] 2 [/SUP], Siti Naqiah Amrun[SUP] 1 [/SUP], Nicholas Kim-Wah Yeo[SUP] 1 [/SUP], Hsiuyi V Chen[SUP] 1 [/SUP], Matthew Zirui Tay[SUP] 1 [/SUP], Guillaume Carissimo[SUP] 1 4 [/SUP]; COVID-19 Study Group[SUP] 1 [/SUP]; NCID Study Group[SUP] 5 [/SUP]; Seow Yen Tan[SUP] 6 [/SUP], Yee-Sin Leo[SUP] 3 5 7 8 [/SUP], David C Lye[SUP] 3 5 7 8 [/SUP], Laurent Renia[SUP] 1 9 10 [/SUP], Barnaby Edward Young[SUP] 3 5 7 [/SUP], Lisa F P Ng[SUP] 1 10 11 12 [/SUP]
Affiliations
Long-term complications from coronavirus disease 2019 (COVID-19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination may reduce sequela. We conducted a prospective longitudinal study on hospitalized patients over 24 months. Clinical symptoms were collected by self-reporting during follow-up, along with blood samples for quantification of inflammatory markers and immune cell frequencies. All patients were given one dose of mRNA vaccine at 12-16 months. Their immune profiles at 12 and 24 months were compared. Approximately 37% and 39% of our patients reported post-COVID-19 symptoms at 12 and 24 months, respectively. The proportion of symptomatic patients with more than one symptom decreased from 69% at 12 months to 56% at 24 months. Longitudinal cytokine profiling revealed a cluster of individuals with persistently high inflammatory cytokine levels 12 months after infection. Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. The majority of inflammatory markers and dysregulated immune cells in vaccinated patients recovered to a healthy baseline at 24 months, even though symptoms persisted. Post-COVID-19 symptoms can linger for 2 years after the initial infection and are associated with prolonged inflammation. Prolonged inflammation in hospitalized patients resolves after 2 years. We define a set of analytes associated with persistent inflammation and presence of symptoms, which could be useful biomarkers for identifying and monitoring high-risk survivors.
Keywords: COVID vaccine; biomarkers; inflammation; long COVID; subclinical signs.
. 2023 May;95(5):e28774.
doi: 10.1002/jmv.28774. Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
Siew-Wai Fong[SUP] 1 [/SUP], Yun Shan Goh[SUP] 1 [/SUP], Anthony Torres-Ruesta[SUP] 1 [/SUP], Zi Wei Chang[SUP] 1 [/SUP], Yi-Hao Chan[SUP] 1 [/SUP], Vanessa Kexin Neo[SUP] 1 [/SUP], Bernett Lee[SUP] 2 3 [/SUP], Kaibo Duan[SUP] 2 [/SUP], Siti Naqiah Amrun[SUP] 1 [/SUP], Nicholas Kim-Wah Yeo[SUP] 1 [/SUP], Hsiuyi V Chen[SUP] 1 [/SUP], Matthew Zirui Tay[SUP] 1 [/SUP], Guillaume Carissimo[SUP] 1 4 [/SUP]; COVID-19 Study Group[SUP] 1 [/SUP]; NCID Study Group[SUP] 5 [/SUP]; Seow Yen Tan[SUP] 6 [/SUP], Yee-Sin Leo[SUP] 3 5 7 8 [/SUP], David C Lye[SUP] 3 5 7 8 [/SUP], Laurent Renia[SUP] 1 9 10 [/SUP], Barnaby Edward Young[SUP] 3 5 7 [/SUP], Lisa F P Ng[SUP] 1 10 11 12 [/SUP]
Affiliations
- PMID: 37212320
- DOI: 10.1002/jmv.28774
Long-term complications from coronavirus disease 2019 (COVID-19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination may reduce sequela. We conducted a prospective longitudinal study on hospitalized patients over 24 months. Clinical symptoms were collected by self-reporting during follow-up, along with blood samples for quantification of inflammatory markers and immune cell frequencies. All patients were given one dose of mRNA vaccine at 12-16 months. Their immune profiles at 12 and 24 months were compared. Approximately 37% and 39% of our patients reported post-COVID-19 symptoms at 12 and 24 months, respectively. The proportion of symptomatic patients with more than one symptom decreased from 69% at 12 months to 56% at 24 months. Longitudinal cytokine profiling revealed a cluster of individuals with persistently high inflammatory cytokine levels 12 months after infection. Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. The majority of inflammatory markers and dysregulated immune cells in vaccinated patients recovered to a healthy baseline at 24 months, even though symptoms persisted. Post-COVID-19 symptoms can linger for 2 years after the initial infection and are associated with prolonged inflammation. Prolonged inflammation in hospitalized patients resolves after 2 years. We define a set of analytes associated with persistent inflammation and presence of symptoms, which could be useful biomarkers for identifying and monitoring high-risk survivors.
Keywords: COVID vaccine; biomarkers; inflammation; long COVID; subclinical signs.